Lupin, a Mumbai-based pharma and the largest drug manufacturing capacities in India with 11 manufacturing plants, and currently working on almost 100 percent capacity utilization is planning to invest over US$50 million this year to create additional manufacturing capacities, including a new multipurpose formulation manufacturing facility at a special economic zone at Indore, Madhya Pradesh, conform to the U.S. Food and Drug Administration and other leading regulatory standards.  

The US$507 million Lupin has filed about 51 Abbreviated New Drug Applications with the U.S. FDA and so far received 23 product approvals. Lupin is also looking to acquire companies in Latin America, Japan and the Middle East.